| 摘要 |
<p>An N-hydroxy sulfonyl butanamide compound that inter alia inhibits matrix metalloprotease activity is disclosed as is a treatment process that comprises administering a contemplated N-hydroxy sulfonyl butanamide compound in an MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metall protease activity.</p> |
